# GAIA Biomedical Interface and Biosafety Spec v1.0

**Document Type:** Canonical Technical Specification
**Version:** 1.0
**Date:** 2026-03-14
**Authority:** GAIA Governance Council / VITA Core
**Applies To:** All GAIA subsystems that interface with clinical data, biomedical devices, biological research, or public health systems

---

## 1. Purpose

This specification defines the requirements for GAIA's interfaces with biomedical systems, clinical decision support, public health data infrastructure, and biological research. It also defines biosafety constraints that govern how GAIA handles, models, and responds to biological risk information.

---

## 2. Governing Standards

- **HL7 FHIR R4/R5** — Healthcare interoperability standard
- **DICOM** — Medical imaging standard
- **ICD-11 / SNOMED CT / LOINC** — Clinical terminology standards
- **HIPAA / GDPR** — Patient data privacy (US and EU)
- **FDA 21 CFR Part 11** — Electronic records in clinical contexts
- **FDA guidance on Clinical Decision Support Software** (2022)
- **WHO Laboratory Biosafety Manual (4th edition)**
- **NIH / OSTP Dual Use Research of Concern (DURC) policy**
- **CDC Select Agent regulations**
- **One Health framework (WHO/FAO/UNEP/WOAH)**

---

## 3. Clinical Decision Support Interface

### 3.1 Classification
GAIA clinical outputs must be classified per FDA CDS guidance:
- **Non-device CDS:** General wellness information, not intended to replace clinical judgment
- **Device CDS:** Outputs intended to inform specific clinical decisions — requires SIL 2+ compliance and FDA pre-submission review before deployment

### 3.2 Required Disclosures
All GAIA clinical decision support outputs must include:
- evidence basis and tier rating
- model confidence level
- statement that output does not replace professional clinical judgment
- clear indication when the query exceeds GAIA's validated scope

### 3.3 FHIR Integration
- All patient data exchange must use HL7 FHIR R4 minimum
- GAIA must never store identified patient data without explicit consent and data processing agreement
- De-identification must follow HIPAA Safe Harbor or Expert Determination method
- FHIR resources must be validated against official profiles before ingestion

---

## 4. Biomedical Data Governance

- Patient data is classified as GAIA sensitivity level CRITICAL
- Access to patient data requires role-based authorization, logged access, and purpose limitation
- Data minimization: GAIA must request only the minimum data fields required for each task
- Retention: identified patient data must not be retained beyond the session unless explicit consent is given
- All biomedical data flows must be documented in a data processing register

---

## 5. Biosafety Policy

### 5.1 Biological Risk Classification
GAIA must not generate, synthesize, or optimize:
- novel pathogen enhancement strategies
- synthesis routes for select agents or toxins
- any biological design intended to increase transmissibility, virulence, or immune evasion

This prohibition applies regardless of stated purpose and cannot be overridden by any user, administrator, or governance actor.

### 5.2 Dual Use Research of Concern (DURC)
When GAIA receives queries that may touch DURC domains:
- GUARDIAN must evaluate the query against the DURC policy checklist
- Queries that match DURC patterns must be flagged, logged, and referred to human review
- GAIA must not provide step-by-step technical assistance for DURC-categorized research without explicit institutional biosafety committee authorization

### 5.3 WHO Biosafety Level Awareness
GAIA must maintain awareness of WHO Biosafety Levels (BSL 1–4):
- Recommendations involving BSL-3 or BSL-4 organisms must carry explicit safety warnings
- GAIA must not recommend procedures that exceed the requesting institution's stated containment capability

---

## 6. Public Health Data Integration

- GAIA may integrate anonymized surveillance data from WHO, CDC, ECDC, and equivalent bodies
- Outbreak modeling outputs must be labeled as models, not ground-truth predictions
- GAIA must not publish or amplify unverified outbreak claims
- Epidemic modeling must include uncertainty bounds and be reviewed by VITA core before external release

---

## 7. VITA Core Responsibilities

The VITA consciousness core is the primary owner of all biomedical and biosafety functions:
- maintains the clinical ontology and FHIR resource registry
- enforces the biosafety prohibition list
- routes DURC-adjacent queries to GUARDIAN for review
- monitors public health data feeds and surfaces anomalies to human operators
- coordinates with TERRA and AQUA for One Health cross-domain analysis
